COMPANY RESEARCHLevostar Biotech, based in Suzhou, supports nucleic acid and cell and gene therapy projects with plasmid services, RNA synthesis and delivery development, and analytical testing. Its mRNA offering includes sequence design, template construction, RNA production, and LNP formulation. The targeted LNP platform describes antibody conjugation and particle characterization. Manufacturing grade and suitability for a clinical regulatory submission must be confirmed for each project.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Official materials describe plasmid process services, RNA synthesis and delivery development, and analytical and quality studies.
The mRNA platform combines design, templates, RNA production, formulation, and analytical support.
Targeted LNP services include antibody conjugation and measurements of particle size, antibody-positive particles, and antibody copy number.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| RNA / LNP service platform | Project-specific · Project-specific | Services / platform | No claim of platform-wide clinical validation. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.
Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
